Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Demetrios Petropoulos Image

      Demetrios Petropoulos, MD

      Department of Pediatrics, Division of Pediatrics

      About Dr. Demetrios Petropoulos

      Patient Load: Neuroradiology: About 20-40 diagnostic cases per day, with average 3 myelograms, 2 spinal interventions and 1 angiogram/spinal interventional procedure per week. Regular scheduled and unscheduled consultations are performed with referring
      Read More

      Present Title & Affiliation

      Primary Appointment

      Professor, Critical Care, Section of Integrated Ethics in Cancer Care, The University of Texas MD Anderson Cancer Center

      Professor, Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      1986University of Athens Medical School, Athens, GR, MD

      Postgraduate Training

      1993-1997Fellowship, Pediatric Hematology/Oncology, Pediatrics Hematology Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
      1990-1993Residency, Pediatrics, Pediatrics, University of Texas Health Science Center, Houston, Texas
      1989-1989Residency, Internal Medicine, Internal Medicine, 401 General Army Hospital, Athens

      Licenses & Certifications

      2003Medical License, TX Medical Board
      1997Pediatrics Board Examination, Greece
      1996Pediatric Hematology/Oncology Subspecialty Board
      1995Medical License. Indiana Medical Board
      1994The American Board of Pediatrics
      1989Medical License. Greece

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

      Assistant Professor, Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2011

      Other Professional Positions

      Attending, Pediatric Hematologist, St. Sophia Children's Hospital, Athens, 1998 - 2002

      Extramural Institutional Committee Activities

      Chair, Pediatric Quality and Safety Meeting, The University of Texas MD Anderson Cancer Center, 2015 - Present

      Member, Institutional Review Board 3, The University of Texas MD Anderson Cancer Center, 2011 - Present

      Alternate Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2011 - Present

      Associate Member, Institutional Review Board 3, The University of Texas MD Anderson Cancer Center, 2010 - 2011

      Vice Chair, Institutional Review Board 5, The University of Texas MD Anderson Cancer Center, 2010 - Present

      Member, Clinical Ethics Consultation Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2011

      Member, Institutional Review Board 5, The University of Texas MD Anderson Cancer Center, 2009 - 2010

      Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2008 - 2011

      Associate Member, Institutional Review Board 5, The University of Texas MD Anderson Cancer Center, 2008 - 2009

      Member, Clinical Ethics Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2009

      Member, Order Set Steering Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present

      Member, Chemotherapy/Bioimmunotherapy Work Group, The University of Texas MD Anderson Cancer Center, 2007 - Present

      Member, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2006 - Present

      Member, Antiemetic Task Force, The University of Texas MD Anderson Cancer Center, 2003 - Present

      Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2007

      Honors & Awards

      2007 - 2009Residents' Teaching Award
      1996Berlex Oncology Foundation Award: Pharmacology of Anticancer Drugs
      1994M. D. Anderson Cancer Center PRS Research Award for Clinical Trainees
      1986Graduated Summa Cum Laude, University of Athens Medical School

      Professional Memberships

      Foundation for the Accreditation of Cellular Therapy

      2007 - Present

      Pediatric Bone Marrow Transplant Consortium

      2007 - Present

      Children's Oncology Group

      2006 - Present

      American Society of Blood and Marrow Transplantation

      2005 - Present

      American Society of Hematology

      2002 - Present

      Greek Medical Association

      1999 - Present

      European Blood and Marrow Transplantation Group

      1998 - Present

      Selected Presentations & Talks

      National Presentations

      1. 2010. Thiotepa (TT), Busulfan (Bu), And Clofarabine (Clo) As A Conditioning Therapy For Allogeneic Hematopoetic Stem Cell Transplant For Patients With High Risk Malignancies: Early Response And Engraftment Data. Poster presentation. Conference. Thiotepa (TT), Busulfan (Bu), And Clofarabine (Clo) As A Conditioning Therapy For Allogeneic Hematopoetic Stem Cell Transplant For Patients With High Risk Malignancies: Early Response And Engraftment Data. Poster presentation. Orlando, FL, US.
      2. 2009. Utility of Insuflon Catheters After Pediatric Hematopoietic Stem Cell Transplantation: Taking the Pain Out Of Subcutaneous Injections. Poster presentation. Conference. Utility of Insuflon Catheters After Pediatric Hematopoietic Stem Cell Transplantation: Taking the Pain Out Of Subcutaneous Injections. Poster presentation. Tampa, FL, US.
      3. 2009. Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Poster presentation. Conference. Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Poster presentation. Tampa, FL, US.
      4. 2008. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Oral presentation. Conference. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Oral presentation. San Francisco, CA, US.
      5. 2008. Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Oral presentation. Conference. Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Oral presentation. San Francisco, CA, US.
      6. 2008. Central Nervous System (CNS) Involvement at Diagnosis does not Adversely Affect the Outcome of High-Dose Chemotherapy and Transplant for Patients with Acute Myeloid Leukemia (AML). Poster presentation. Conference. Central Nervous System (CNS) Involvement at Diagnosis does not Adversely Affect the Outcome of High-Dose Chemotherapy and Transplant for Patients with Acute Myeloid Leukemia (AML). Poster presentation. San Diego, CA, US.
      7. 2008. Incidence and Risk Factors for Chronic Graft-Versus-Host Disease (cGVHD) after Cord Blood Transplantation (CBT). Poster presentation. Conference. Incidence and Risk Factors for Chronic Graft-Versus-Host Disease (cGVHD) after Cord Blood Transplantation (CBT). Poster presentation. San Diego, CA, US.
      8. 2008. Plasma B-type Natriuretic Peptide: Its Role in Pediatric Hematopoietic Stem CellTransplantation and Implications for Nurses. Poster presentation. Conference. Plasma B-type Natriuretic Peptide: Its Role in Pediatric Hematopoietic Stem CellTransplantation and Implications for Nurses. Poster presentation. San Diego, CA, US.
      9. 2008. Double Cord Blood Transplants in Pediatric Patients: Implications for Nurses – what is all the Hype about? Poster presentation. Conference. Double Cord Blood Transplants in Pediatric Patients: Implications for Nurses – what is all the Hype about? Poster presentation. San Diego, CA, US.
      10. 2008. A Prospective Evaluation of the Effect of Polyoma (BK) Virus Infection on the Incidence of Hemorrhagic Cystitis (HC) after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT). Poster presentation. Conference. A Prospective Evaluation of the Effect of Polyoma (BK) Virus Infection on the Incidence of Hemorrhagic Cystitis (HC) after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT). Poster presentation. San Diego, CA, US.
      11. 2007. Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP). Poster presentation. Conference. Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP). Poster presentation. Atlanta, GA, US.
      12. 2007. Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes. Poster presentation. Conference. Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes. Poster presentation. Atlanta, GA, US.
      13. 2007. Impact of Host-versus-Graft HLA mismatches on survival after UCBT. Oral presentation. Conference. Impact of Host-versus-Graft HLA mismatches on survival after UCBT. Oral presentation. Los Angeles, CA, US.
      14. 2007. Delayed immune recovery after UCBT is characterized by thymic regeneration failure. Oral presentation. Conference. Delayed immune recovery after UCBT is characterized by thymic regeneration failure. Oral presentation. Los Angeles, CA, US.
      15. 2007. High-dose thiotepa, busulfan, and cyclophosphamide for allogeneic stem cell transplantation in pediatric patients with high-risk leukemias. Poster presentation. Conference. High-dose thiotepa, busulfan, and cyclophosphamide for allogeneic stem cell transplantation in pediatric patients with high-risk leukemias. Poster presentation. Keystone, CO, US.
      16. 2007. Development of a multidisciplinary prospective study to evaluate the prevalence of BK virus in hemorrhagic cystitis (HC) patients in unrelated donor hematopoietic stem cell transplantation (UD HSCT) recipients. Poster presentation. Conference. Development of a multidisciplinary prospective study to evaluate the prevalence of BK virus in hemorrhagic cystitis (HC) patients in unrelated donor hematopoietic stem cell transplantation (UD HSCT) recipients. Poster presentation. Keystone, CO, US.
      17. 2006. Delayed immune recovery after umbilical cord blood transplantation (UCBT) is characterized by thymic regeneration failure. Oral presentation. Conference. Delayed immune recovery after umbilical cord blood transplantation (UCBT) is characterized by thymic regeneration failure. Oral presentation. Orlando, FL, US.
      18. 2006. Donor-recipient host-versus-graft (HVG) HLA mismatches and outcome of cord blood transplants (CBT). Oral presentation. Conference. Donor-recipient host-versus-graft (HVG) HLA mismatches and outcome of cord blood transplants (CBT). Oral presentation. Orlando, FL, US.
      19. 2005. Total body irradiation, fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Oral presentation. Conference. Total body irradiation, fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Oral presentation. Los Angeles, CA, US.
      20. 2004. Autologous Stem Cell Transplantation (SCT) in pediatric patients with advanced Hodgkin’s Lymphoma (HL): the role of Interferon-alpha post-transplant . Poster presentation. Conference. Autologous Stem Cell Transplantation (SCT) in pediatric patients with advanced Hodgkin’s Lymphoma (HL): the role of Interferon-alpha post-transplant . Poster presentation. Coronado Springs, FL, US.
      21. 2004. Total Body Irradiation (TBI), Fludarabine (F), Melphalan (M) and allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for advanced pediatric hematologic malignancies. Poster presentation. Conference. Total Body Irradiation (TBI), Fludarabine (F), Melphalan (M) and allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for advanced pediatric hematologic malignancies. Poster presentation. San Diego, CA, US.

      International Presentations

      1. 2008. Immune Reconstitution after cord blood transplant. Oral presentation. Conference. Immune Reconstitution after cord blood transplant. Oral presentation. Athens, GR.
      2. 2007. Tacrolimus and short-term methotrexate for graft versus host disease prophylaxis after unrelated single unit cord blood transplant in pediatric patients: A single center experience. Poster presentation. Conference. Tacrolimus and short-term methotrexate for graft versus host disease prophylaxis after unrelated single unit cord blood transplant in pediatric patients: A single center experience. Poster presentation. Paris, FR.
      3. 2006. Evaluation of the chimeric status of children with haemoglobinopathies treated with stem cell transplantation. Poster presentation. Conference. Evaluation of the chimeric status of children with haemoglobinopathies treated with stem cell transplantation. Poster presentation. Hamburg, DE.
      4. 2005. Origin of bone marrow mesenchymal stem cells derived from isolated CD105+ cells in patients undergoing allogeneic stem cell transplantation. Conference. Origin of bone marrow mesenchymal stem cells derived from isolated CD105+ cells in patients undergoing allogeneic stem cell transplantation. Prague, CZ.
      5. 2004. A pilot study of high dose cyclophosphamide, melphalan and topotecan with peripheral blood stem cell rescue for treatment of high risk neuroblastoma. Poster presentation. Conference. A pilot study of high dose cyclophosphamide, melphalan and topotecan with peripheral blood stem cell rescue for treatment of high risk neuroblastoma. Poster presentation. Oslo, NO.
      6. 2002. Haemopoietic Stem Cell transplantation for Thalassaemic syndromes: The Greek experience.Oral presentation. Conference. Haemopoietic Stem Cell transplantation for Thalassaemic syndromes: The Greek experience.Oral presentation. Santorini, GR.
      7. 2002. Correlation of endoscopic and histologic findings in pediatric allogeneic hematopoietic stem cell transplant (HSCT) recipients with diarrhea. Poster presentation. Conference. Correlation of endoscopic and histologic findings in pediatric allogeneic hematopoietic stem cell transplant (HSCT) recipients with diarrhea. Poster presentation. Geneva, CH.
      8. 2000. Monitoring of chimerism by PCR in pediatric patients after allogeneic haematopoietic stem cell transplantation (HSCT) Poster presentation. Conference. Monitoring of chimerism by PCR in pediatric patients after allogeneic haematopoietic stem cell transplantation (HSCT) Poster presentation. Rhodes, GR.
      9. 2000. Ex vivo expansion of high proliferative potential-quiescent (HPP-Q) human haematopoietic stem cells Poster presentation. Conference. Ex vivo expansion of high proliferative potential-quiescent (HPP-Q) human haematopoietic stem cells Poster presentation. Rhodes, GR.
      10. 1999. Cytokine-mediated proliferation of AC 133+ cord blood cells and selective differentiation to megakaryocytic and erythroid lineages Poster presentation. Conference. Cytokine-mediated proliferation of AC 133+ cord blood cells and selective differentiation to megakaryocytic and erythroid lineages Poster presentation. Barcelona, ES.
      11. 1999. The oral manifestations in early diagnosis of cGVHD. Role of apoptosis in differences in clinical expression Poster presentation. Conference. The oral manifestations in early diagnosis of cGVHD. Role of apoptosis in differences in clinical expression Poster presentation. Hamburg, DE.
      12. 1998. Pulmonary Complications Following Bone Marrow Transplantation (BMT) in children. Poster presentation. Conference. Pulmonary Complications Following Bone Marrow Transplantation (BMT) in children. Poster presentation. Athens, GR.
      13. 1998. Cytomegalovirus infection following Stem Cell transplantation in children Poster presentation. Conference. Cytomegalovirus infection following Stem Cell transplantation in children Poster presentation. Florence, IT.
      14. 1998. Central Venous Catheter Thrombosis in children Undergoing Bone Marrow Transplantation (BMT). Poster presentation. Conference. Central Venous Catheter Thrombosis in children Undergoing Bone Marrow Transplantation (BMT). Poster presentation. Athens, GR.

      Formal Peers

      1. 2008. Confidence Intervals: What do they mean and why do we care?. Invited. Houston, TX, US.
      Read More
      Less

      Selected Publications

      Peer-Reviewed Articles

      1. Frost, M, Okeleji, O, Elgehiny, A, Harrison, DJ, Herzog, CE, Connors, JS, Petropoulos, D, Tewari, P, Ragoonanan, D, Nieto, Y, Sheikh, IN. Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors. Pediatric Blood and Cancer 73(6), 2026. e-Pub 2026. PMID: 41889248.
      2. Raj, R, Catueno, S, Gibson, A, McCall, DC, Garcia, MB, Nunez, CA, Roth, M, Sasaki, K, Tewari, P, Issa, GC, Farhat, A, Connors, JS, Sheikh, IN, Nishida, Y, Yi, JS, Stevens, A, Bataller Torralba, A, Bhalla, K, Petropoulos, D, Daver, N, Kadia, TM, Cuglievan, B, DiNardo, C. FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood 146(21):2608-2611, 2025. e-Pub 2025. PMID: 40971491.
      3. Fan, AE, Alqahtani, S, Garnes, ND, Tewari, P, Petropoulos, D, Khazal, SJ, Mahadeo, KM, DePriest, P, Sheikh, IN. Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients. Pediatric Blood and Cancer 72(10), 2025. e-Pub 2025. PMID: 40879561.
      4. Pasvolsky, O, Bassett Jr, R, Ghanem, S, Cuglievan, B, Tewari, P, Hosing, C, Srour, S, Ramdial, JL, Mahadeo, KM, Khazal, SJ, Petropoulos, D, Popat, UR, Qazilbash, MH, Kebriaei, P, Champlin, RE, Shpall, E, Nieto, Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC cancer 23(1), 2023. e-Pub 2023. PMID: 38124057.
      5. Sheikh IN, Alqahtani S, Ragoonanan D, Tewari P, Petropoulos D, Mahadeo KM, Popat U, Shpall EJ, Khazal S. Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia. Int J Mol Sci 23(15), 2022. e-Pub 2022. PMID: 35955881.
      6. Gardner MK, Amado PJ, Baig MU, Mohiuddin S, Harden A, Ewing LJ, Razvi S, Cortes JA, Mejia R, Petropoulos D, Tewari P, Ahmad AH. Implementing Rounding Checklists in a Pediatric Oncologic Intensive Care Unit. Children (Basel) 9(4), 2022. e-Pub 2022. PMID: 35455624.
      7. Tambaro FP, Ragoonanan D, Tewari P, Petropoulos D, Aung FM, Mahadeo KM, Khazal S. The Role of Granulocyte Transfusions in Optimizing Candidacy for Chimeric Antigen Receptor T-Cell Therapy in Patients With Treatment-refractory Infections. J Pediatr Hematol Oncol 44(2):e463-e466, 2022. e-Pub 2022. PMID: 33625094.
      8. Gibson A, Ragoonanan D, Tewari P, Petropoulos D, Rodriguez N, DiNardo C, Mahadeo KM, Khazal S. Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita. Pediatr Transplant 26(2):e14157, 2022. e-Pub 2022. PMID: 34626046.
      9. Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13:1032397, 2022. e-Pub 2022. PMID: 36439104.
      10. Ragoonanan D, Bhar S, Mohan G, Beltramo F, Khazal SJ, Hurley C, Andersen C, Margossian S, Neelapu SS, Shpall E, Gutierrez C, Tewari P, Shoberu B, Talleur A, McCall D, Nunez C, Cuglievan B, Tambaro FP, Petropoulos D, Abdel-Azim H, Mahadeo KM. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Front Oncol 12:1022901, 2022. e-Pub 2022. PMID: 36353531.
      11. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):468, 2021. e-Pub 2021. PMID: 33731864.
      12. Ragoonanan D, Tambaro FP, Khazal SJ, Tewari P, Petropoulos D, Champlin R, Mahadeo KM. Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. Pediatr Blood Cancer 68(5):e28839, 2021. e-Pub 2021. PMID: 33258192.
      13. Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, Tewari P, Petropoulos D, Shoberu B, Kebriaei P, Mahadeo KM, Tambaro FP. Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading. Bone Marrow Transplant 56(1):175-184, 2021. e-Pub 2021. PMID: 32665674.
      14. Brown BD, Tambaro FP, Kohorst M, Chi L, Mahadeo KM, Tewari P, Petropoulos D, Slopis JM, Sadighi Z, Khazal S. Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?. Front Oncol 11:634445, 2021. e-Pub 2021. PMID: 33763368.
      15. Tambaro FP, Khazal S, Nunez C, Ragoonanan D, Tewari P, Petropoulos D, Kebriaei P, Wierda WG, Mahadeo KM. Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clin Case Rep 8(9):1678-1681, 2020. e-Pub 2020. PMID: 32983475.
      16. Kohorst MA, Khazal SJ, Tewari P, Petropoulos D, Mescher B, Wang J, Mahadeo KM, Kelley JM. Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients. EClinicalMedicine 26:100514, 2020. e-Pub 2020. PMID: 32964199.
      17. Kohorst MA, Nunez CA, Tewari P, Petropoulos D, Mahadeo KM, Neelapu SS, Shpall EJ, Khazal S. Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. Br J Haematol 190(2):e114-e117, 2020. e-Pub 2020. PMID: 32469086.
      18. Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol. e-Pub 2020. PMID: 32619033.
      19. Harden A, Ragoonanan D, Anildes-Gubman D, McCall D, Faltus K, Featherston S, Shoberu B, Moffet JR, Petropoulos D, Khazal SJ, Razvi S, Mahadeo KM, Tewari P. Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. Front Oncol 10:1227, 2020. e-Pub 2020. PMID: 32850365.
      20. Maher OM, Silva JG, Wu J, Liu D, Cooper LJ, Tarek N, Worth L, Lee DA, Petropoulos D, Franklin AR, Zweidler-Mckay P, Wells RJ, Rondon G, Champlin RE, Tewari P. Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. Pediatr Transplant 21(3), 2017. e-Pub 2017. PMID: 28160352.
      21. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
      22. Parmar S, de Lima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin R. Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplant 49(8):1109-12, 2014. e-Pub 2014. PMID: 24797184.
      23. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG conditioning for unrelated cord blood transplantation. Leuk Lymphoma 53(5):901-6, 2012. e-Pub 2012. PMID: 21988645.
      24. Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattone A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 95(7):1183-90, 2010. e-Pub 2010. PMID: 20410183.
      25. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, Worth L, Cooper LJ, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJ. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. Blood 110(13):4543-51, 2007. e-Pub 2007. PMID: 17671230.
      26. Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, Shpall EJ, Rolston KV, Raad II, Chan KW, Champlin RE. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant Infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 86(6):324-33, 2007. e-Pub 2007. PMID: 18004177.
      27. Costelloe CM, Eftekhari F, Petropoulos D. Radiography of successful bone marrow transplantation for osteopetrosis. Skeletal Radiol 36 Suppl. 1:34-7, 2007. e-Pub 2007. PMID: 16799785.
      28. Petropoulos D, Worth LL, Mullen CA, Lockhart S, Choroszy M, Chan KW. Interferon alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkins' lymphoma. Bone Marrow Transplant 38(5):345-9, 2006. e-Pub 2006. PMID: 16915224.
      29. Petropoulos D, Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M, Ha CS, Champlin RC, Chan KW. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Bone Marrow Transplant 37(5):463-7, 2006. e-Pub 2006. PMID: 16435013.
      30. Vlachopapadopoulou E, Kitra V, Peristeri J, Goussetis E, Karachaliou F, Petropoulos D, Fotinou A, Michalacos S, Graphakos S. Gonadal function of young patients with beta-thalassemia following bone marrow transplantation. J Pediatr Endocrinol Metab 15:477-483, 2005. e-Pub 2005.
      31. Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 10(11):805-12, 2004. e-Pub 2004. PMID: 15505611.
      32. Nicolatou-Galitis O, Kitra V, Van Vliet-Constantinidou C, Peristeri J, Goussetis E, Petropoulos D, Grafakos S. The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. J Oral Pathol Med 30(3):148-53, 2001. e-Pub 2001. PMID: 11271629.
      33. Kattamis AC, Antoniadis M, Manoli I, Kitra V, Petropoulos D, Grafakos S. Endocrine problems in ex-thalassemic patients. Transfus Sci 23(3):251-2, 2000. e-Pub 2000. PMID: 11099906.
      34. Peristeri J, Kitra V, Goussetis E, Petropoulos D, Theodosaki M, Kattamis A, Graphakos S. Haematopoietic stem cell transplantation for the management of haemoglobinopathies in Greek patients. Transfus Sci 23(3):263-4, 2000. e-Pub 2000. PMID: 11099911.
      35. Goussetis E, Theodosaki M, Paterakis G, Peristeri J, Petropoulos D, Kitra V, Papassarandis C, Graphakos S. A functional hierarchy among the CD34+ hematopoietic cells based on in vitro proliferative and differentiative potential of AC133+CD34(bright) and AC133(dim/)-CD34+ human cord blood cells. J Hematother Stem Cell Res 9(6):827-40, 2000. e-Pub 2000. PMID: 11177594.
      36. Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 26(5):463-70, 2000. e-Pub 2000. PMID: 11019834.
      37. Gussetis E, Peristeri J, Kitra V, Kattamis A, Petropoulos D, Papassotiriou I, Graphakos S. Combined umbilical cord blood and bone marrow transplantation in the treatment of beta-thalassemia major. Pediatr Hematol Oncol 17:307-14, 2000. e-Pub 2000. PMID: 10845229.
      38. Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone Marrow Transplant 24(9):947-52, 1999. e-Pub 1999. PMID: 10556952.
      39. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha S, Kuttesch JF, Rolston KV. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86:126-34, 1999. e-Pub 1999. PMID: 10391572.
      40. Przepiorka D, Petropoulos D, Mullen CA, Danielson M, Mattewada V, Chan KW. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. Bone Marrow Transplant 23(12):1291-5, 1999. e-Pub 1999. PMID: 10414918.
      41. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha S, Kuttesch JF, Rolston KV. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol 21:212-8, 1999. e-Pub 1999. PMID: 10363854.
      42. Jr AL, Petropoulos D, Everse LA, Mullen CA. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Cancer Res 59(7):1525-30, 1999. e-Pub 1999. PMID: 10197624.
      43. Mullen CA, Anderson L, Woods K, Nishino M, Petropoulos D. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. Hum Gene Ther 9(14):2019-30, 1998. e-Pub 1998. PMID: 9759929.
      44. Mullen CA, Petropoulos D, Rytting M, Jeha S, Zipf T, Roberts WM, Rolston KV. Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia. J Pediatr Hematol Oncol 20(5):516-7, 1998. e-Pub 1998. PMID: 9787333.
      45. Maltezou HC, Petropoulos D, Gardner M, Abi-Said D, Mantzouranis EC, Rolston KV I, Chan KW. Varicella-Zoster virus infection in children with hematopoietic stem cell transplants. Int J Pediatr Hemato Oncol 5:345-351, 1998. e-Pub 1998.
      46. Chan KW, Petropoulos D, Choroszy M, Herzog C, Jaffe N, Ater J, Korbling M. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant 20(12):1039-43, 1997. e-Pub 1997. PMID: 9466276.
      47. Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res 56(6):1361-6, 1996. e-Pub 1996. PMID: 8640826.
      48. Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB, al E. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. Bone Marrow Transplant 16(6):737-41, 1995. e-Pub 1995. PMID: 8750262.

      Invited Articles

      1. Petropoulos D, Chan KW. Umbilical cord blood transplantation. Curr Oncol Rep 7(6):406-9, 2005. e-Pub 2005. PMID: 16221376.

      Review Articles

      1. Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
      2. Ragoonanan D, Sheikh IN, Gupta S, Khazal SJ, Tewari P, Petropoulos D, Li S, Mahadeo KM. The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Biomedicines 10(9), 2022. e-Pub 2022. PMID: 36140387.
      3. Sheikh IN, Ragoonanan D, Franklin A, Srinivasan C, Zhao B, Petropoulos D, Mahadeo KM, Tewari P, Khazal SJ. Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830969.
      4. Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P, Bhatti M, Ahmad AH, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill JB, Zaky W, Daw N, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Mahadeo KM. Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol 11:625707, 2021. e-Pub 2021. PMID: 33614514.
      5. Dao L, Ragoonanan D, Yi S, Swinford R, Petropoulos D, Mahadeo KM, Li S. The Organ Trail: A Review of Biomarkers of Organ Failure. Front Oncol 10:579219, 2020. e-Pub 2020. PMID: 33262945.
      6. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, (PALISI) Network PALIASI. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 16(1):45-63, 2019. e-Pub 2019. PMID: 30082906.
      7. Petropoulos D, Chan KW. Carlecortemcel-l: an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation. Expert Opin Biol Ther 9(11):1437-44, 2009. e-Pub 2009. PMID: 19785569.
      8. Maltezou HC, Petropoulos D, Choroszy M, Gardner M, Mantzouranis EC, Rolston KV, Chan KW. Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 20(10):879-81, 1997. e-Pub 1997. PMID: 9404930.

      Editorials

      1. Okeleji, O, McCall, DC, Gibson, A, Garcia, MB, Nunez, CA, Roth, M, Connors, JS, Petropoulos, D, Tewari, P, Cuglievan, B, Sheikh, IN. Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia. Blood Advances 9(8):1988-1990, 2025. PMID: 39993239.

      Abstracts

      1. Maher O, Cooper L, Tarek N. Successful treatment for secondary AML and MDS following myeloablative hematopoetic stem cell transplantation for children, adolescents and young adults. Bone Marrow Transplantation 49(1s):S 376, 2014. e-Pub 2014.
      2. Worth LL, Andersson BS, Kazerooni R, Petropoulos D, Kelly SS, Lee DA, Du M, Madden TL, de Lima MJ, Champlin RE, Copper LJ. Thiotepa (TT), Busulfan (Bu), And Clofarabine (Clo) As A Conditioning Therapy For Allogeneic Hematopoetic Stem Cell Transplant For Patients With High Risk Malignancies: Early Response And Engraftment Data. Biology of Blood and Marrow Transplantation 16(2 (Suppl 1)):292-3, 2010. e-Pub 2010.
      3. de Lima M, McNiece I, McMannis J, Hosing C, Kebriaei P, Komanduri K, Worth L, Staba S, Cooper L, Petropoulos D, Lee D, Jones R, Nieto Y, Andersson B, Korbling M, Alousi A, Qazilbash M, Popat U, Khouri I, Bollard C, Leen A, Rondon G, Molldrem J, Champlin R, Simmons P, Shpall E. Double Cord Blood Transplantation (CBT) With Ex-Vivo Expansion (EXP) of One Unit Utilizing A Mesenchymal Stromal Cell (MSC) Platform. Biology of Blood and Marrow Transplantation 15(2 (Suppl 1)), 2009. e-Pub 2009.
      4. Prokopiou C, Koontz S, Rosipal N, Worth L, Petropoulos D, Kelly S, Lee D, Cooper L. Utility of Insuflon Catheters After Pediatric Hematopoietic Stem Cell Transplantation: Taking the Pain Out Of Subcutaneous Injections. Biology of Blood and Marrow Transplantation 15(2 (Suppl 1)), 2009. e-Pub 2009.
      5. Ciurea S, Kebraei P, Khouri I, Qazilbash M, Jones R, Petropoulos D, Worth L, Alousi A, Hosing C, Cano P, McMannis J, Giralt S, Fernandez-Vina M, Shpall E, Lima M. Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 15(2 (Suppl 1)), 2009. e-Pub 2009.
      6. Ciurea S, Kebriaei P, Khouri I, Qazilbash M, Jones R, Petropoulos D, Worth L, Alousi A, Hosing C, Patah P, Cano P, McMannis J, Giralt S, Fernandez-Vina M, Champlin R, Shpall E, and Lima M. High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Blood 112(11), 2008. e-Pub 2008.
      7. de Lima M, McMannis J, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, Silva L, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson B, Nieto Y, Ciurea S, Komanduri K, Champlin R, and Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood 112(11), 2008. e-Pub 2008.
      8. Saliba RM, Couriel D, Komanduri K, Patah P, Westin J, Giralt S, Cooper L, Petropoulos D, Worth L, Safdar A, Champlin RE, Shpall EJ, de Lima M. Incidence and Risk Factors for Chronic Graft-Versus-Host Disease (cGVHD) after Cord Blood Transplantation(CBT). Biol Blood Marrow Transplant 14(2 (Suppl 1)):132-33 (Abst 362), 2008. e-Pub 2008.
      9. Carstens KA, Ortiz JM, Koontz SE, Worth LL, Petropoulos D, Lee DA, de Lima MJ, Shpall E, Cooper LJ. Double Cord Blood Transplants in Pediatric Patients: Implications for Nurses – what is all the Hype about?. Biol Blood Marrow Transplant 14(2):161 (Abst 454), 2008. e-Pub 2008.
      10. Bertin HD, Koontz SE, Petropoulos D, Worth LL, Lee DA, Cooper LJ. Plasma B-type Natriuretic Peptide: Its Role in Pediatric Hematopoietic Stem Cell Transplantation and Implications for Nurses. Biol Blood Marrow Transplant 14(2 (Suppl 1)):160 (Abst 452), 2008. e-Pub 2008.
      11. Petropoulos D, Giralt SA, Andersson BS, Chan KW, Rondon G, Popat UR, Hosing C, Alousi AM, Champlin RE, de Lima MJ. Central Nervous System (CNS) Involvement at Diagnosis does not Adversely Affect the Outcome of High-Dose Chemotherapy and Transplant for Patients with Acute Myeloid Leukemia (AML). Biol Blood Marrow Transplant 14(2 (Suppl 1)):61-62 (Abst 165), 2008. e-Pub 2008.
      12. Silva L, Patah P, Szewczyk N, Saliba RM, Gilman L, Gulbis A, Neumann J, Walker JA, Petropoulos D, El-Zimaity M, Anderlini P, Tarrand J, Ciurea SO, Shpall E, Popat U, Jones R, Giralt S, Champlin RE, de Lima M. A Prospective Evaluation of the Effect of Polyoma (BK)Virus Infection on the Incidence of Hemorrhagic Cystitis (HC) after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT). Biol Blood Marrow Transplant 14(2 (Suppl 1)):102-3 (Abst 277), 2008. e-Pub 2008.
      13. Silva L, Patah P, Saliba R, Szewczyk N, Gilman L, Gulbis A, Neumann J, Walker J. Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood 112(11), 2008. e-Pub 2008.
      14. Couriel D, Patah P, Saliba R, Cooper L, Worth L, Petropoulos D, Depadua L, Zhang W, Giralt S, Champlin R, Shpall EJ, de Lima M. Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes. Blood 110(11):Abst 2977, 2007. e-Pub 2007.
      15. de Lima M, McMannis J, Komanduri K, Worth L, Karandish S, Jones R, Giralt S, Cooper L, Padua L, Patah P, Petropoulos D, Thall P, Zhang W, Qiao W, Robinson S, Qureshi S, Khouri I, Hosing C, Alousi A, Rondon G, Andersson BS, Champlin R, Shpall EJ. Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP). Blood 110(11):Abst 2014, 2007. e-Pub 2007.
      16. Komanduri KV, John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Hosing C, Couriel DM, de Lima M, Shpall EJ. Delayed immune recovery after umbilical cord blood transplantation (UCBT) is characterized by thymic regeneration failure. Biol Blood Marrow Transplant 13(11):1400 (Abst 20), 2007. e-Pub 2007.
      17. de Lima M, Patah PA, Saliba R, Couriel D, Chan KW, Worth L, Giralt S, Kebriae P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri KV, Champlin RE, Shpall EJ. Donor-recipient host-versus-graft (HVG) human leukocyte antigen mismatches and outcome of cord blood transplants (CBT). Biol Blood Marrow Transplant 13(11):1393 (Abst 2), 2007. e-Pub 2007.
      18. Petropoulos D, Worth L, Koontz SE, Choroszy MS, Chan KW, Shpall EJ, Champlin RE. Tacrolimus and Short-Term Methotrexate (mini-MTX) for Graft Versus Host Disease (GVHD) Prophylaxis after Unrelated Single Unit Cord Blood Transplant (CBT) in Pediatric Patients. Blood 110(11):Abst 5018, 2007. e-Pub 2007.
      19. Petropoulos D, Chan KW, Worth LL, Choroszy MS, Koontz SE, Shpall EJ, Champlin RE, Cooper LJ. Tacrolimus and short-term methotrexate for graft versus host disease prophylaxis after unrelated single unit cord blood transplant in pediatric patients: A single center experience. Proceedings of the Euro Conference: Biology and Clinical Applications of cord blood cells, Paris, France, 2007. e-Pub 2007.
      20. Worth LL, Koontz SE, Petropoulos D, Tran HT, Choroszy MS, Chan KW. High-dose thiotepa, busulfan, and cyclophosphamide for allogeneic stem cell transplantation in pediatric patients with high-risk leukemias. Biol Blood Marrow Transplant 13(2 (Suppl 1)):68 (Abst 183), 2007. e-Pub 2007.
      21. Szweczyk NA, Gilman LA, Neumann J, Gulbis A, Walker JA, Patah PA, Petropoulos D, El-Zimaity M, Anderlini P, Tarrand J, Champlin RE, de Lima M. Development of a multidisciplinary prospective study to evaluate the prevalence of BK virus in hemorrhagic cystitis (HC) patients in unrelated donor hematopoietic stem cell transplantation (UD HSCT) recipients. Biol Blood Marrow Transplant 13(2 (Suppl 1)):148 (Abst 415), 2007. e-Pub 2007.
      22. de Lima M, Patah PA, Saliba R, Couriel D, Chan KW, Worth L, Giralt S, Kebriaei P, Khouri I, Cooper L, Fernandez-Vina M, Cano P, Petropoulos D, McMannis J, Hosing C, Rondon G, Komanduri KV, Champlin RE, Shpall EJ. Donor-recipient host-versus-graft (HVG) HLA mismatches and outcome of cord blood transplants (CBT). Blood 108(11):Abst 436, 2006. e-Pub 2006.
      23. Komanduri KV, St John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Couriel DR, de Lima M, Shpall EJ. Delayed immune recovery after umbilical cord blood transplantation (UCBT) is characterized by thymic regeneration failure. Blood 108(11):Abst 312, 2006. e-Pub 2006.
      24. Theodosaki M, Petrakou E, Goussetis E, Kitra V, Peristeri I, Petropoulos D, Vessalas G, Graphakos S. Evaluation of the chimeric status of children with haemoglobinopathies treated with stem cell transplantation. Bone Marrow Transplant 37(Suppl 1):S 134 (Abst P585), 2006. e-Pub 2006.
      25. Patah PA, Szewczyk NA, Gilman L, Gulbis A, Neumann J, Walker JA, Petropoulos D, El-Zimaity M, Anderlini P, Tarrand J, Champlin RE, de Lima M. Blood. Does polyoma (BK) virus contribute to development of hemorrhagic cystitis (HC) in unrelated donor allogeneic hematopoietic stem cell transplantation (UD HSCT) recipients? A prospective evaluation 108(11):Abst 5282, 2006. e-Pub 2006.
      26. Petropoulos D. Total body irradiation, fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Biol Blood Marrow Tranplant 11(11):937-8 (Abst 24), 2005. e-Pub 2005.
      27. Kitra V, Tzanoudaki M, Vrachnou E, Goussetis E, Peristeri I, Petropoulos D, Vessalas G, Kanariou M, Graphakos S. Study of immune reconstitution and its impact on the outcome in children with acute leukaemia following hematopoietic stem cell transplantation. Bone Marrow Transplant 35(Suppl 2):S 264 (Abst P 881), 2005. e-Pub 2005.
      28. Spiropoulou A, Theodosaki M, Goussetis E, Stefanaki K, Peristeri I, Kitra V, Petropoulos D, Ferdinadou I, Grafakos S. Origin of bone marrow mesenchymal stem cells derived from isolated CD105+ cells in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 33(Suppl 1):S 87-8 (Abst 433), 2004. e-Pub 2004.
      29. Petropoulos D, Worth LL, Mullen CA, Lockhart S, Ramirez I, Chan KW. Autologous stem cell transplantation (SCT) in pediatric patients with advanced Hodgkin's lymphoma (HL): the role of interferon-alpha post-transplant. Biol Blood Marrow Transplant 10(Suppl 1):79 (Abst 213), 2004. e-Pub 2004.
      30. Ater J, Worth L, Petropoulos D, Choroszy M, Chan KW. A pilot study of high dose cyclophosphamide, melphalan and topotecan with peripheral blood stem cell rescue for treatment of high risk neuroblastoma. Pediatric Blood and Cancer 43(4):Abst PD090, 2004. e-Pub 2004.
      31. Petropoulos D, Mullen CA, Worth LL, Lockhart S, Ramirez I, Choroszy MS, Chan KW. Inteferon-alpha after autologous stem cell transplantation (SCT) in pediatric patients with advanced Hodgkin’s lymphoma (HL). Pediatric Research 55(4):311A (Abst 1771), 2004. e-Pub 2004.
      32. Petropoulos D, Worth LL, Mullen CA, Mahajan A, Choroszy M, Chan KW. Total body irradiation (TBI), fludarabine (F), Melphalan (M) and allogeneic hematopoietic stem cell transplantation (HSCT) for advanced pediatric hematologic malignancies. Blood 104(11):506a (Abst 1827), 2004. e-Pub 2004.
      33. Peristeri I, Kitra V, Goussetis E, Petropoulos D, Graphakos S. Hemopoietic stem cell transplantation for thalassemic syndromes: the Greek experience. Bone Marrow Transplant 29(Suppl 2):S137-8 (Abst P559), 2002. e-Pub 2002.
      34. Stefanaki K, Petropoulos D, Kitra V, Peristeri I, Goussetis E, Karentzou O, Graphakos S. Immunohistochemical study of acute graft versus host disease (aGVHD). Bone Marrow Transplant 29(Suppl 2):S180-1 (Abst P679), 2002. e-Pub 2002.
      35. Theodosaki M, Kalogeri E, Kitra V, Petropoulos D, Peristeri J, Goussetis E, Graphakos S. Serial analysis of chimeric status by PCR in haematopoietic stem cell transplanted patients. Bone Marrow Transplant 27(Suppl 1):S240 (Abst P 626), 2001. e-Pub 2001.
      36. Kitra V, Vlachopapadopoulou E, Petropoulos D, Peristeri J, Goussetis E, Karahaliou K, Theodosaki M, Mihalakos S, Graphakos S. Thyroid and gonadal function in pediatric thalassemic patients following BMT. Bone Marrow Transplant 27(Suppl 1):S194-5 (Abst P 529), 2001. e-Pub 2001.

      Book Chapters

      1. Rytting ME, Choroszy MS, Petropoulos D, Chan KW. Acute leukemia. In: Pediatric Oncology. Springer Science and Business Media, Inc, 1-17, 2005.
      2. Ater JL, Weinberg JS, Maor MH, Petropoulos D. Brain tumors: Chemotherapy and investigational therapy. In: Pediatric Oncology. Springer Science and Business Media, Inc, 50-69, 2005.
      3. Chan KW, Petropoulos D, Chang EL, Rytting ME. Hodgkin Lymphoma and Non-Hodgkin Lymphoma. In: Pediatric Oncology. Springer Science and Business Media, Inc, 18-29, 2005.

      Letters to the Editor

      1. Okeleji, O, McCall, DC, Cuglievan, B, Gibson, A, Petropoulos, D, Tewari, P, Connors, JS, Sheikh, IN. Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab. British Journal of Haematology 208: 1462-1466, 2026.
      2. Sheikh, IN, Alqahtani, S, Okeleji, O, Brown, BD, Ragoonanan, D, Waseemuddin, M, Shoberu, B, Kawedia, J, Khazal, SJ, Connors, JS, Petropoulos, D, Tewari, P, Bonfim, C, Driscoll, TA, DePriest, BP, Mahadeo, KM. Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes. Bone marrow transplantation 61: 241-244, 2026.
      3. Okeleji, O, Khazal, SJ, Mahadeo, KM, Ragoonanan, D, Rodriguez, NI, DiNardo, C, Connors, JS, Petropoulos, D, Tewari, P, Sheikh, IN. Allogeneic Hematopoietic Stem Cell Transplant for an Unknown Inherited Bone Marrow Failure Syndrome With a Novel Compound Heterozygous Mutation. Pediatric Blood and Cancer 72, 2025.
      4. Sheikh, IN, Uwaezuoke, D, Okeleji, O, Quesada, AE, Herzog, CE, Ragoonanan, D, Tewari, P, Petropoulos, D, McCall, DC, Nunez, CA, Roth, M, Cuglievan, B, Khazal, SJ. Treatment of a Pediatric Patient with Core Binding Factor Acute Myeloid Leukemia Post-Cytotoxic Therapy With Cytarabine, Daunorubicin, and Gemtuzumab Followed by Stem Cell Transplantation. Pediatric Blood and Cancer 72, 2025.
      Read More
      Less

      Patient Reviews


      CV information above last modified July 22, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top